Silditop 100 mg contains Sildenafil Citrate, a PDE5 inhibitor most commonly used to treat erectile dysfunction (ED). However, Sildenafil is also FDA-approved under the brand name Revatio for the treatment of Pulmonary Arterial Hypertension (PAH)—a serious condition involving high blood pressure in the arteries of the lungs.

In PAH, the pulmonary arteries become narrowed or stiffened, making it harder for the heart to pump blood through the lungs. Sildenafil helps by relaxing and widening the blood vessels in the lungs, reducing pulmonary pressure and improving the heart's efficiency. This results in increased exercise capacity, reduced fatigue, and better oxygen delivery throughout the body.

While Silditop 100 mg is not officially marketed for PAH, it contains the same active ingredient as Revatio, though the dosages differ. For PAH, Sildenafil is typically prescribed at lower doses (20 mg three times daily). Using Silditop off-label for PAH should only be done under strict medical supervision, as inappropriate dosing can lead to side effects like low blood pressure, dizziness, vision changes, or heart complications.

In summary, Sildenafil plays a significant role in managing PAH by lowering lung artery pressure and improving quality of life—but must be used cautiously and under a doctor’s care.